公开(公告)号：EP3624804A1

公开(公告)日：2020-03-25

申请号：EP18801840.2

申请日：2018-05-15

申请人： Annji Pharmaceutical Co., Ltd.

发明人： CHERN, Ji-Wang ,  YU, Chao-Wu ,  LIU, Jia-Rong ,  HO, Yi-Hsun ,  WU, Chia-Yu ,  HUANG, Chan-Hui ,  HUNG, Pei-Yun

IPC分类号： A61K31/517 ,  C07D239/88 ,  C07D239/91 ,  C07D239/96

公开(公告)号：EP4161908A1

公开(公告)日：2023-04-12

申请号：EP21736832.3

申请日：2021-06-08

申请人： Annji Pharmaceutical Co., Ltd.

发明人： YU, Chao-Wu ,  HUNG, Pei-Yun ,  JAGTAP, Ajit Dhananjay ,  HO, Yi-Hsun ,  CHIANG, Hsin-Yi

IPC分类号： C07D239/91 ,  A61P25/02 ,  A61K31/517

公开(公告)号：EP2836484B1

公开(公告)日：2017-06-14

申请号：EP13775887.6

申请日：2013-04-02

申请人： Annji Pharmaceutical Co., Ltd.

发明人： CHERN, Ji-Wang ,  YU, Chao-Wu ,  CHANG, Pei-Teh

IPC分类号： C07D403/06 ,  C07D239/91 ,  A61K31/517 ,  A61P35/00

CPC分类号： A61K31/517 ,  C07D239/91 ,  C07D403/06

公开(公告)号：EP2836484A1

公开(公告)日：2015-02-18

申请号：EP13775887.6

申请日：2013-04-02

申请人： Annji Pharmaceutical Co., Ltd.

发明人： CHERN, Ji-Wang ,  YU, Chao-Wu ,  CHANG, Pei-Teh

IPC分类号： C07D239/90

CPC分类号： A61K31/517 ,  C07D239/91 ,  C07D403/06

摘要： Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit are also disclosed. In an embodiment of the invention, the compound is (2E)-3-(2-ethyl-6-fluoro-3,4-dihydro-4-oxo-3-phenethylquina20lin-7-yl)-N-hydroxyacrylamide, or a salt thereof. In another embodiment of the invention, the compound is (2E)-3-(2-ethyl-7-f1uoro-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide, (2E)-3-(7-chloro-2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide, or a salt thereof. In another aspect the invention relates to a composition comprising a therapeutically effective amount of a compound as aforementioned, or a pharmaceutically acceptable salt, a solvate or hydrate, a prodrug, or a metabolite thereof, and a pharmaceutically acceptable carrier or vehicle.